CVS Health
CVSNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $89.01 Prior regular-session close from the quote source.
- $87.45–$89.52 Regular-session low and high so far today.
- 11.1M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $69.51–$110.68 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own CVS if the company converts that scale into sustained margin recovery after recent compression.
CVS price history
Loading recent earnings…
Investment thesis
What must happen next
CVS's large base of recurring prescription and benefits demand produces resilient revenue growth that is relatively insensitive to normal retail cycles.StrengtheningMateriality: High
Revenue grew each year: $292,111,000,000 (2021) -> $322,467,000,000 (2022) -> $357,776,000,000 (2023) -> $372,809,000,000 (2024) -> $402,067,000,000 (2025). If revenue is resilient, the company can fund investments and cash returns even in tougher macro periods; if prescriptions decline or migrate away, top-line durability is gone.
Watch: Loss of major PBM or benefits contracts to competitors (e.g., UnitedHealth/OptumRx, Amazon Pharmacy, or other national PBMs) or rapid migration of prescription fulfillment to low-cost online channels.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Revenue grew each year: $292,111,000,000 (2021) -> $322,467,000,000 (2022) -> $357,776,000,000 (2023) -> $372,809,000,000 (2024) -> $402,067,000,000 (2025).
Open source ↗If CVS realizes care‑management and cross‑business synergies from its integrated retail/PBM/health-services footprint, that should re-lever revenue into higher operating income; failure to realize those synergies (or regulatory limits on PBM fees) will keep operating income depressed.HoldingMateriality: High
Historically high operating income (e.g., $13,743,000,000 in 2023) demonstrates the company can generate meaningful operating profits from its model. Operating income determines profitability, free cash and EPS upside; durable recovery is necessary for valuation rerating.
Watch: Operating income collapsed from $13.7B (2023) to $8.52B (2024) to $4.66B (2025), indicating either one-off headwinds or a structural pressure on margins.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Historically high operating income (e.g., $13,743,000,000 in 2023) demonstrates the company can generate meaningful operating profits from its model.
Open source ↗Because pharmacy and benefits businesses are cash-generative, operating cash flow should remain positive and fund capex, dividends and some buybacks even if operating income lags for a period.StrengtheningMateriality: Medium
Operating cash flow remained positive across years: $16,177,000,000 (2022) -> $13,426,000,000 (2023) -> $9,107,000,000 (2024) -> $10,639,000,000 (2025). Sustained positive operating cash flow preserves flexibility to invest and return capital; if cash conversion falls away, CVS may need to cut returns or raise external capital.
Watch: Worsening working capital (e.g., slower collections from payers or higher claims outflows) that materially reduces cash conversion.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating cash flow remained positive across years: $16,177,000,000 (2022) -> $13,426,000,000 (2023) -> $9,107,000,000 (2024) -> $10,639,000,000 (2025).
Open source ↗CVS's cash balance plus recurring operating cash flow gives it balance-sheet optionality to fund strategy and shareholder returns without immediate heavy external financing.HoldingMateriality: Medium
Cash and cash equivalents have been in the multi-billion range: $12,945,000,000 (2022) -> $8,196,000,000 (2023) -> $8,586,000,000 (2024) -> $8,453,000,000 (2025). If true, management can invest in growth or return capital; if false, CVS may be forced into dilution or debt at unfavorable terms.
Watch: Large acquisition or settlement that consumes cash (or materially increases liabilities) or a sustained drop in operating cash flow would force external financing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents have been in the multi-billion range: $12,945,000,000 (2022) -> $8,196,000,000 (2023) -> $8,586,000,000 (2024) -> $8,453,000,000.
Open source ↗EPS is highly sensitive to operating-margin swings; absent margin recovery, EPS will not compound even with growing revenue because prior profit per dollar has fallen.WeakeningMateriality: Medium
EPS declined materially as operating income fell: diluted EPS $6.47 (2023) -> $3.66 (2024) -> $1.39 (2025), showing high leverage between margins and EPS. Investors seeking EPS growth need margin improvement, not just top-line growth; further margin compression will depress per-share returns.
Watch: If management achieves rapid synergies, cost cuts, or favorable pricing, EPS could recover despite recent declines.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
EPS declined materially as operating income fell: diluted EPS $6.47 (2023) -> $3.66 (2024) -> $1.39 (2025), showing high leverage.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
CVS's large base of recurring prescription and benefits demand produces resilient revenue growth that is relatively insensitive to normal retail cycles. If revenue is resilient, the company can fund investments and cash returns even in tougher macro periods; if prescriptions decline or migrate away, top-line durability is gone.
If CVS realizes care‑management and cross‑business synergies from its integrated retail/PBM/health-services footprint, that should re-lever revenue into higher operating income; failure to realize those synergies (or regulatory limits on PBM fees) will keep operating income depressed. Operating income determines profitability, free cash and EPS upside; durable recovery is necessary for valuation rerating.
Because pharmacy and benefits businesses are cash-generative, operating cash flow should remain positive and fund capex, dividends and some buybacks even if operating income lags for a period. Sustained positive operating cash flow preserves flexibility to invest and return capital; if cash conversion falls away, CVS may need to cut returns or raise external capital.
CVS's cash balance plus recurring operating cash flow gives it balance-sheet optionality to fund strategy and shareholder returns without immediate heavy external financing. If true, management can invest in growth or return capital; if false, CVS may be forced into dilution or debt at unfavorable terms.
EPS is highly sensitive to operating-margin swings; absent margin recovery, EPS will not compound even with growing revenue because prior profit per dollar has fallen. Investors seeking EPS growth need margin improvement, not just top-line growth; further margin compression will depress per-share returns.
All standing thesis claims
Original report summary
the company converts that scale into sustained margin recovery after recent compression.
Bull case and bear case
Bull case and bear case for CVS HEALTH
Where the evidence on CVS HEALTH disagrees: Mixed on the latest evidence (Oct 12, 2026). Of its 5 thesis points, 2 strengthening, 2 holding and 1 weakening.
Bull case: what the evidence supports
CVS's large base of recurring prescription and benefits demand produces resilient revenue growth that is relatively insensitive to normal retail cycles.
If CVS realizes care‑management and cross‑business synergies from its integrated retail/PBM/health-services footprint, that should re-lever revenue into higher operating income; failure to realize those synergies (or regulatory limits on PBM fees) will keep operating income depressed.
Because pharmacy and benefits businesses are cash-generative, operating cash flow should remain positive and fund capex, dividends and some buybacks even if operating income lags for a period.
CVS's cash balance plus recurring operating cash flow gives it balance-sheet optionality to fund strategy and shareholder returns without immediate heavy external financing.
Bear case: what the evidence questions
EPS is highly sensitive to operating-margin swings; absent margin recovery, EPS will not compound even with growing revenue because prior profit per dollar has fallen.
Thesis-Break Engine
Thesis-break watch · CVS HEALTH
Loading the break-condition record for CVS HEALTH.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDirector or principal officer change.
CVS HEALTH filed an SEC 8-K on 2026-08-17: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
CVS HEALTH filed an SEC 8-K on 2026-08-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
CVS HEALTH filed an SEC 8-K on 2026-05-18: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Loss of major PBM or benefits contracts to competitors (e.g., UnitedHealth/OptumRx, Amazon Pharmacy, or other national PBMs) or rapid migration of prescription fulfillment to low-cost online channels.
- Operating income collapsed from $13.7B (2023) to $8.52B (2024) to $4.66B (2025), indicating either one-off headwinds or a structural pressure on margins.
- Worsening working capital (e.g., slower collections from payers or higher claims outflows) that materially reduces cash conversion.
- Large acquisition or settlement that consumes cash (or materially increases liabilities) or a sustained drop in operating cash flow would force external financing.
- If management achieves rapid synergies, cost cuts, or favorable pricing, EPS could recover despite recent declines.
CVS news
Loading headlines…
Financial statements
CVS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
CVS: quick answers
- Which well-known investors own CVS?
- 4 of the 37 well-known funds tracked here reported CVS shares in their latest 13F filings. By share of the fund's portfolio: Fairfax Financial (Prem Watsa), 10.6%; Glenview Capital Management, 9.1%; Viking Global Investors (Andreas Halvorsen), 1.1%. Fund portfolios
CVS in well-known investors’ portfolios
4 of 37 funds reported CVS shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Prem WatsaFairfax Financial | 10.6% | $281M | No change | Q2 2026 |
| Glenview Capital Management | 9.1% | $499M | −41.1% | Q2 2026 |
| Andreas HalvorsenViking Global Investors | 1.1% | $379M | New | Q2 2026 |
| Ray DalioBridgewater Associates | 0.19% | $45.6M | −28.7% | Q2 2026 |